vs
MANNKIND CORP（MNKD）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
MANNKIND CORP的季度营收约是RIGEL PHARMACEUTICALS INC的1.6倍（$112.0M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -14.2%，领先398.3%），MANNKIND CORP同比增速更快（45.8% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 30.0%）
曼凯德公司是一家生物制药企业，成立于1991年2月，总部位于美国康涅狄格州丹伯里，专注于糖尿病、肺动脉高压等疾病治疗药物的研发、生产及商业化推广，致力于为相关患者提供创新的治疗方案。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
MNKD vs RIGL — 直观对比
营收规模更大
MNKD
是对方的1.6倍
$69.8M
营收增速更快
MNKD
高出24.6%
21.2%
净利率更高
RIGL
高出398.3%
-14.2%
两年增速更快
RIGL
近两年复合增速
30.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.0M | $69.8M |
| 净利润 | $-15.9M | $268.1M |
| 毛利率 | 87.6% | 91.5% |
| 营业利润率 | -6.9% | 33.2% |
| 净利率 | -14.2% | 384.0% |
| 营收同比 | 45.8% | 21.2% |
| 净利润同比 | -314.9% | 1769.2% |
| 每股收益（稀释后） | $-0.05 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MNKDRIGL
| Q4 25 | $112.0M | $69.8M | ||
| Q3 25 | $82.1M | $69.5M | ||
| Q2 25 | $76.5M | $101.7M | ||
| Q1 25 | $78.4M | $53.3M | ||
| Q4 24 | $76.8M | $57.6M | ||
| Q3 24 | $70.1M | $55.3M | ||
| Q2 24 | $72.4M | $36.8M | ||
| Q1 24 | $66.3M | $29.5M |
净利润MNKDRIGL
| Q4 25 | $-15.9M | $268.1M | ||
| Q3 25 | $8.0M | $27.9M | ||
| Q2 25 | $668.0K | $59.6M | ||
| Q1 25 | $13.2M | $11.4M | ||
| Q4 24 | $7.4M | $14.3M | ||
| Q3 24 | $11.6M | $12.4M | ||
| Q2 24 | $-2.0M | $-1.0M | ||
| Q1 24 | $10.6M | $-8.2M |
毛利率MNKDRIGL
| Q4 25 | 87.6% | 91.5% | ||
| Q3 25 | 94.5% | 93.2% | ||
| Q2 25 | 94.0% | 95.6% | ||
| Q1 25 | 95.2% | 91.7% | ||
| Q4 24 | 93.7% | 89.9% | ||
| Q3 24 | 95.4% | 85.5% | ||
| Q2 24 | 92.3% | 92.4% | ||
| Q1 24 | 94.2% | 93.1% |
营业利润率MNKDRIGL
| Q4 25 | -6.9% | 33.2% | ||
| Q3 25 | 23.0% | 40.9% | ||
| Q2 25 | 6.9% | 60.1% | ||
| Q1 25 | 28.5% | 23.9% | ||
| Q4 24 | 34.5% | 28.9% | ||
| Q3 24 | 18.2% | 25.4% | ||
| Q2 24 | 22.9% | 1.2% | ||
| Q1 24 | 25.2% | -23.6% |
净利率MNKDRIGL
| Q4 25 | -14.2% | 384.0% | ||
| Q3 25 | 9.7% | 40.2% | ||
| Q2 25 | 0.9% | 58.6% | ||
| Q1 25 | 16.8% | 21.5% | ||
| Q4 24 | 9.7% | 24.9% | ||
| Q3 24 | 16.5% | 22.5% | ||
| Q2 24 | -2.8% | -2.8% | ||
| Q1 24 | 16.0% | -27.9% |
每股收益（稀释后）MNKDRIGL
| Q4 25 | $-0.05 | $14.11 | ||
| Q3 25 | $0.03 | $1.46 | ||
| Q2 25 | $0.00 | $3.28 | ||
| Q1 25 | $0.04 | $0.63 | ||
| Q4 24 | $0.03 | $0.82 | ||
| Q3 24 | $0.04 | $0.70 | ||
| Q2 24 | $-0.01 | $-0.06 | ||
| Q1 24 | $0.04 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $171.3M | $155.0M |
| 总债务越低越好 | $354.6M | $52.5M |
| 股东权益账面价值 | $-51.0M | $391.5M |
| 总资产 | $792.2M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资MNKDRIGL
| Q4 25 | $171.3M | $155.0M | ||
| Q3 25 | $260.0M | $137.1M | ||
| Q2 25 | $179.0M | $108.4M | ||
| Q1 25 | $181.5M | $77.1M | ||
| Q4 24 | $197.3M | $77.3M | ||
| Q3 24 | $251.6M | $61.1M | ||
| Q2 24 | $247.8M | $49.1M | ||
| Q1 24 | $300.7M | $49.5M |
总债务MNKDRIGL
| Q4 25 | $354.6M | $52.5M | ||
| Q3 25 | $109.7M | $60.0M | ||
| Q2 25 | $36.2M | $60.0M | ||
| Q1 25 | $36.1M | $60.0M | ||
| Q4 24 | $36.1M | $60.0M | ||
| Q3 24 | $227.9M | $60.0M | ||
| Q2 24 | $227.6M | $60.0M | ||
| Q1 24 | $264.1M | $60.0M |
股东权益MNKDRIGL
| Q4 25 | $-51.0M | $391.5M | ||
| Q3 25 | $-44.6M | $117.6M | ||
| Q2 25 | $-55.0M | $81.9M | ||
| Q1 25 | $-58.6M | $18.6M | ||
| Q4 24 | $-78.8M | $3.3M | ||
| Q3 24 | $-209.9M | $-14.6M | ||
| Q2 24 | $-225.8M | $-29.9M | ||
| Q1 24 | $-230.0M | $-31.7M |
总资产MNKDRIGL
| Q4 25 | $792.2M | $513.6M | ||
| Q3 25 | $494.6M | $242.5M | ||
| Q2 25 | $411.7M | $206.7M | ||
| Q1 25 | $410.1M | $176.0M | ||
| Q4 24 | $393.8M | $164.0M | ||
| Q3 24 | $464.2M | $139.4M | ||
| Q2 24 | $443.8M | $128.4M | ||
| Q1 24 | $480.9M | $126.5M |
负债/权益比MNKDRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $-10.0M | — |
| 自由现金流率自由现金流/营收 | -8.9% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $13.7M | — |
8季度趋势，按日历期对齐
经营现金流MNKDRIGL
| Q4 25 | $-8.0M | $22.0M | ||
| Q3 25 | $23.6M | $24.0M | ||
| Q2 25 | $8.9M | $30.5M | ||
| Q1 25 | $-6.4M | $-893.0K | ||
| Q4 24 | $22.6M | $14.5M | ||
| Q3 24 | $9.3M | $21.7M | ||
| Q2 24 | $3.8M | $302.0K | ||
| Q1 24 | $6.7M | $-5.0M |
自由现金流MNKDRIGL
| Q4 25 | $-10.0M | — | ||
| Q3 25 | $22.5M | — | ||
| Q2 25 | $7.8M | — | ||
| Q1 25 | $-6.7M | — | ||
| Q4 24 | $19.7M | — | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $861.0K | — | ||
| Q1 24 | $4.3M | — |
自由现金流率MNKDRIGL
| Q4 25 | -8.9% | — | ||
| Q3 25 | 27.4% | — | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | -8.6% | — | ||
| Q4 24 | 25.7% | — | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 6.5% | — |
资本支出强度MNKDRIGL
| Q4 25 | 1.8% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 3.6% | — |
现金转化率MNKDRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 2.96× | 0.86× | ||
| Q2 25 | 13.40× | 0.51× | ||
| Q1 25 | -0.48× | -0.08× | ||
| Q4 24 | 3.05× | 1.01× | ||
| Q3 24 | 0.81× | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.63× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MNKD
| Products | $50.4M | 45% |
| Royalty | $33.6M | 30% |
| Afrezza | $22.9M | 20% |
| V Go | $4.3M | 4% |
RIGL
暂无分部数据
